journal
MENU ▼
Read by QxMD icon Read
search

Hematological Oncology

journal
https://www.readbyqxmd.com/read/28332735/non-hodgkin-lymphoma-in-south-east-asia-an-analysis-of-the-histopathology-clinical-features-and-survival-from-thailand
#1
Tanin Intragumtornchai, Udomsak Bunworasate, Kitsada Wudhikarn, Arnuparp Lekhakula, Jakrawadi Julamanee, Kanchana Chansung, Chittima Sirijerachai, Lalita Norasetthada, Weerasak Nawarawong, Archrob Khuhapinant, Noppadol Siritanaratanakul, Tontanai Numbenjapon, Kannadit Prayongratana, Suporn Chuncharunee, Pimjai Niparuck, Tawatchai Suwanban, Nongluk Kanitsap, Somchai Wongkhantee, Rutchanid Pornvipavee, Peerapon Wong, Nisa Makruasi, Pongsak Wannakrairot, Thamathorn Assanasen, Sanya Sukpanichnant, Paisarn Boonsakan, Wasana Kanoksil, Charin Ya-In, Kanita Kayasut, Winyu Mitranun, Naree Warnnissorn
Systemic reports on the descriptive epidemiology of non-Hodgkin lymphoma (NHL) from Southeast Asia are scarce. A nationwide multi-institutional registry was conducted to compare the histopathology, clinical features, and survival of Thai adult patients with NHL using large registries, especially those from Far East Asia (FEA). Using a web-based registry system, 13 major medical centers from the 4 geographic regions of Thailand prospectively collected, from 2007 to 2014, the diagnostic pathology, according to the World Health Organization classification, 2008, clinical features and survival of 4056 patients who were newly diagnosed with NHL...
March 23, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28332734/existence-of-jak2-mutation-19%C3%A2-years-prior-to-the-development-of-overt-polycythemia-vera
#2
LETTER
Yutaka Shimazu
No abstract text is available yet for this article.
March 23, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28332724/efficacy-and-safety-of-biosimilar-epoetin-alpha-in-patients-with-chronic-lymphoid-neoplasms-and-chemotherapy-induced-anaemia-an-observational-retrospective-monocentric-analysis
#3
Alessandro Broccoli, Lisa Argnani, Vittorio Stefoni, Letizia Gandolfi, Pier Luigi Zinzani
Epoetin biosimilars are an alternative to originator erythropoietic agents in the treatment of chemotherapy-induced anaemia; however, their effects in patients with lymphoproliferative disorders remain unclear. This analysis examined the response of patients with lymphoproliferative disorders experiencing chemotherapy-induced anaemia to 4- or 8-week treatment with the biosimilar epoetin alpha. Treatment was initiated at first occurrence of haemoglobin (Hb) < 10 g/dL during chemotherapy and was stopped when Hb was >11 g/dL, when chemotherapy was completed, or in case of transfusion dependency...
March 23, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28317148/bortezomib-induced-peripheral-neuropathy-a-genome-wide-association-study-on-multiple-myeloma-patients
#4
Chiara Campo, Miguel Inacio da Silva Filho, Niels Weinhold, Seyed Hamidreza Mahmoudpour, Hartmut Goldschmidt, Kari Hemminki, Maximilian Merz, Asta Försti
The proteasome-inhibitor bortezomib was introduced into the treatment of multiple myeloma more than a decade ago. It is clinically beneficial, but peripheral neuropathy (PNP) is a side effect that may limit its use in some patients. To examine the possible genetic predisposing factors to PNP, we performed a genome-wide association study on 646 bortezomib-treated German multiple myeloma patients. Our aim was to identify genetic risk variants associated with the development of PNP as a serious side effect of the treatment...
March 20, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28219112/brentuximab-vedotin-in-relapsed-refractory-hodgkin-lymphoma-the-hellenic-experience
#5
Maria K Angelopoulou, Theodoros P Vassilakopoulos, Ioannis Batsis, Ioanna Sakellari, Konstantinos Gkirkas, Vasiliki Pappa, Panagiota Giannoulia, Ioannis Apostolidis, Christos Apostolopoulos, Paraskevi Roussou, Panayiotis Panayiotidis, Maria Dimou, Marie-Christine Kyrtsonis, Maria Palassopoulou, Georgios Vassilopoulos, Maria Moschogiannis, Christina Kalpadakis, Dimitrios Margaritis, Alexander Spyridonidis, Eurydiki Michalis, Konstantinos Anargyrou, Panagiotis Repousis, Eleutheria Hatzimichael, Zoi Bousiou, Elias Poulakidas, Dimitrios Grentzelias, Nikolaos Harhalakis, Gerassimos A Pangalis, Achilles Anagnostopoulos, Panagiotis Tsirigotis
This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety-five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty-seven patients received BV after autologous stem cell transplantation failure, whereas 28 patients were treated with BV without a prior autologous stem cell transplantation, due to advanced age/comorbidities or chemorefractory disease...
February 20, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28219109/the-use-of-braf-v600e-mutation-specific-immunohistochemistry-in-pediatric-langerhans-cell-histiocytosis
#6
Leomar Y Ballester, Miguel D Cantu, Karen P H Lim, Stephen F Sarabia, Lizmery Suarez Ferguson, C Renee Webb, Carl E Allen, Kenneth L McClain, Carrie A Mohila, Jyotinder N Punia, Angshumoy Roy, Dolores H López-Terrada, M John Hicks, Kevin E Fisher
BRAF p.V600E mutations are detected in greater than 50% of pediatric Langerhans cell histiocytosis (LCH) lesions. However, the use of mutation-specific BRAF V600E immunohistochemistry (IHC) as a surrogate for molecular testing in pediatric LCH is unknown. We tested the mutation-specific BRAF V600E monoclonal antibody (clone VE1) in formalin-fixed, paraffin-embedded LCH samples from 26 pediatric patients (14 males and 12 females, ages 7 mo-17 y) using allele-specific real-time polymerase chain reaction (PCR) with a limit of detection of 0...
February 20, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28156055/combination-of-rituximab-and-nonpegylated-liposomal-doxorubicin-r-npld-as-front-line-therapy-for-aggressive-non-hodgkin-lymphoma-nhl-in-patients-80%C3%A2-years-of-age-or-older-a-single-center-retrospective-study
#7
Giuseppina Ricciuti, Erica Finolezzi, Stefania Luciani, Elena Ranucci, Massimo Federico, Marta Di Nicola, Isaia Antonio Luca Zecca, Francesco Angrilli
The incidence of non-Hodgkin lymphoma in patients 80 years of age or older is 50 times higher than in 20- to 24-year-olds. Very elderly patients are often not treated with standard immunochemotherapy because of poor performance status, comorbidities, and toxicity concerns. We retrospectively analyzed data for 29 patients diagnosed with diffuse large B-cell lymphoma or grade 3B follicular lymphoma and treated with rituximab in combination with nonpegylated liposomal doxorubicin between January 2010 and August 2015...
February 3, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28156016/severe-pneumonia-associated-with-ibrutinib-monotherapy-for-cll-and-lymphoma
#8
Natalia Kreiniz, Jacob Bejar, Aaron Polliack, Tamar Tadmor
In recent years, there have been major advances in the treatment of chronic lymphocytic leukemia (CLL) particularly since the development of novel therapeutic agents, mostly "biological drugs." One of the obvious advantages of these agents is the decreased rate of infectious complications occurring during the course of therapy, compared to the use of standard immuno-chemotherapy regimens. Here, we describe 3 patients with CLL and 1 with mantle cell lymphoma who developed severe life-threatening pneumonias, during monotherapy with ibrutinib...
February 3, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28156010/refractoriness-to-immunochemotherapy-in-follicular-lymphoma-predictive-factors-and-outcome
#9
Marc Sorigue, Santiago Mercadal, Sara Alonso, Ruben Fernández-Álvarez, Olga García, Miriam Moreno, Helena Pomares, Miguel Alcoceba, Esther González-García, Cristina Motlló, Eva González-Barca, Alejandro Martin, Anna Sureda, Dolores Caballero, Josep-María Ribera, Juan-Manuel Sancho
Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed with stage II to IV follicular lymphoma between 2002 and 2014 and treated with first-line ICT in 4 Spanish institutions were analyzed. Those with no response or progression or relapse within 6 months of first-line response assessment were considered ICT refractory...
February 3, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28105753/efficacy-and-safety-of-high-dose-chemotherapy-with-autologous-stem-cell-transplantation-in-senior-versus-younger-adults-with-newly-diagnosed-multiple-myeloma
#10
Li-Wen Huang, Wendi Bacon, Constance Cirrincione, Bercedis Peterson, Gwynn Long, David Rizzieri, Keith M Sullivan, Kelly Corbet, Mitchell Horwitz, Nelson Chao, Cristina Gasparetto, Sascha A Tuchman
We retrospectively studied 340 fit patients with multiple myeloma (MM) who underwent autologous stem cell transplantation (ASCT). We hypothesized that progression-free survival (PFS) of older patients was non-inferior to that of younger patients after ASCT. Our null hypothesis was that the PFS hazard ratio (HR) for a 5-year increase in age was ≥1.05; the alternative (non-inferiority) hypothesis was that the HR was ≤1. The observed HR was 0.94 (95% confidence interval [CI] 0.86-1.03); since the CI upper bound was <1...
January 19, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28078727/second-cancer-incidence-in-primary-mediastinal-b-cell-lymphoma-treated-with-methotrexate-with-leucovorin-rescue-doxorubicin-cyclophosphamide-vincristine-prednisone-and-bleomycin-regimen-with-or-without-rituximab-and-mediastinal-radiotherapy-results-from-a-monoinstitutional
#11
Vitaliana De Sanctis, Marco Alfò, Alice Di Rocco, Michela Ansuinelli, Eleonora Russo, Mattia F Osti, Maurizio Valeriani, Giuseppe Minniti, Lavinia Grapulin, Daniela Musio, Stefano Bracci, Alessandra Spagnoli, Maria Luisa Moleti, Vincenzo Tombolini, Maurizio Martelli
Our aim is to assess the incidence of second cancer in long-time surviving primary mediastinal B-cell lymphoma (PMBCL) patients treated with combined radiochemoimmunotherapy (standard methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin with rituximab and mediastinal radiation therapy at a dose of 30 to 36 Gy). For this purpose, 92 points were evaluated. After a median overall survival of 137 months (range 76-212), we recorded second cancer in 3 of 80 long-surviving patients (3...
January 12, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28066928/predictive-factors-and-outcomes-for-ibrutinib-therapy-in-relapsed-refractory-mantle-cell-lymphoma-a-real-world-study
#12
Narendranath Epperla, Mehdi Hamadani, Amanda F Cashen, Kwang W Ahn, Eunhye Oak, Abraham S Kanate, Oscar Calzada, Jonathon B Cohen, Luke Farmer, Nilanjan Ghosh, Michael Tallarico, Chadi Nabhan, Luciano J Costa, Vaishalee P Kenkre, Parameswaran N Hari, Timothy S Fenske
Ibrutinib has demonstrated significant activity in relapsed/refractory mantle cell lymphoma (MCL) in clinical trials. However, the impact of hematopoietic cell transplantation on the outcomes of ibrutinib and the predictive factors for ibrutinib response has not been well studied. Hence, we conducted a multicenter retrospective study of MCL patients who received ibrutinib to (1) determine the overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) of ibrutinib in routine clinical practice, (2) examine characteristics predictive of response to ibrutinib therapy, and (3) describe the outcomes of patients failing ibrutinib...
January 8, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28297105/retraction-statement-flt3-beyond-good-and-evil-by-carlos-cortes-penagos-et-al
#13
(no author information available yet)
No abstract text is available yet for this article.
March 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28297104/retraction-statement-overview-of-recent-trends-in-diagnosis-and-management-of-leptomeningeal-multiple-myeloma-by-mahender-r-yellu-jessica-m-engel-abhimanyu-ghose-and-adedayo-a-onitilo
#14
https://www.readbyqxmd.com/read/27353398/indolent-t-and-nk-cell-lymphoproliferative-disorders-of-the-gastrointestinal-tract-a-review-and-update
#15
REVIEW
Rahul Matnani, Karthik A Ganapathi, Suzanne K Lewis, Peter H Green, Bachir Alobeid, Govind Bhagat
Primary gastrointestinal (GI) T- and NK-cell lymphomas are usually aggressive neoplasms associated with high morbidity and mortality. Over the past two decades, however, cases of primary GI lymphoproliferative disorders (LPDs) or lymphomas of T- or NK-cell derivation with indolent behavior have been reported. These LPDs are rare and they can be challenging to diagnose as they share clinical and pathological features with both, inflammatory disorders and aggressive T- and NK-cell lymphomas. Primary, indolent clonal T-cell proliferations of the GI tract, which can be CD4+, CD8+ or CD4- CD8-, have been included as a provisional entity in the newly revised World Health Organization (WHO) classification of lymphoid neoplasms and designated 'indolent T-cell LPD of the GI tract'...
March 2017: Hematological Oncology
https://www.readbyqxmd.com/read/26439896/reduction-of-foxp3-t-cell-subsets-involved-in-incidence-of-chronic-graft-versus-host-disease-after-allogeneic-hematopoietic-stem-cell-transplantation
#16
Yongxian Hu, Qu Cui, Yishan Ye, Yi Luo, Yamin Tan, Jimin Shi, He Huang
Foxp3+ T cells (CD4+ Tregs and CD8+ Treg) have been demonstrated to play roles in the maintenance of tolerance after allogeneic hematopoietic stem cell transplantation (Allo-HSCT). We have found that Foxp3+ γδTCR+ Treg cells (γδTregs) exerted regulatory functions. In the current study, patients were recruited and divided as non-cGVHD, limited cGVHD and extensive cGVHD groups. Healthy volunteers were recruited as healthy group. Treg cells were evaluated by flow cytometry. Serum cytokine levels of IL-2, tumour necrosis factor-α, interferon-γ and transforming growth factor-β1 (TGF-β1) were evaluated by ELISA...
March 2017: Hematological Oncology
https://www.readbyqxmd.com/read/26386260/comparison-of-60-and-80%C3%A2-mg-m-2-of-daunorubicin-in-induction-therapy-of-acute-myeloid-leukaemia
#17
Mohammad Vaezi, Babak Bahar, Asadollah Mousavi, Marjan Yaghmai, Amir Kasaeian, Maryam Souri, Mohammad Jahani, Kamran Alimoghaddam, Ardeshir Ghavamzadeh
For finding better method of acute myeloid leukaemia (AML) induction, we designed a prospective clinical trial to find a more effective regimen with least toxicity for induction therapy of AML. Hence, we examined different accepted doses of daunorubicin and their outcomes. Total of 114 patients were included in the study. Fifty-five patients received 60 mg/m(2) of daunorubicin (arm 1) 1 h IV infusion for 3 days, and the remaining 59 received 80 mg/m(2) (arm 2) 1 h IV infusion for 3 days. Continuous infusion of 100 mg/m(2) /day of cytosine arabinozide IV for 24 h for 7 days was given in both groups...
March 2017: Hematological Oncology
https://www.readbyqxmd.com/read/26354285/concomitant-high-expression-of-toll-like-receptor-tlr-and-b-cell-receptor-bcr-signalling-molecules-has-clinical-implications-in-mantle-cell-lymphoma
#18
Ariz Akhter, Lesley Street, Sunita Ghosh, Bruce F Burns, Ghaleb Elyamany, Meer-Taher Shabani-Rad, Douglas A Stewart, Adnan Mansoor
Mantle cell lymphoma (MCL) is an aggressive disease with frequent relapse. Targeted therapies against B-cell receptor (BCR) molecules have demonstrated improved outcomes in relapsed cases. However, clinical responses are slow and selective, with failure to attain complete remission in a significant subset of patients. Complex interaction of BCR signal transduction with toll-like receptor (TLR) and other pathways in MCL remains unknown, thus averting progress in development of targeted therapies. We have performed detailed digital quantification of BCR/TLR signalling molecules and their effector pathways in a cohort (n = 81) of MCL patients and correlated these data with overall survival...
March 2017: Hematological Oncology
https://www.readbyqxmd.com/read/26310595/induction-consolidation-and-maintenance-therapies-with-arsenic-as-a-single-agent-for-acute-promyelocytic-leukaemia-in-a-11-year-follow-up
#19
Mozaffar Aznab, Mansour Rezaei
The aim of this study was to evaluate the effect of arsenic trioxide as a single agent in acute promyelocytic leukaemia cases for induction, consolidation, and maintenance therapy in a long-term, 11-year follow-up. We studied 60 patients with acute promyelocytic leukaemia. Sixty percent of the patients were aged between 12 and 24 years. Arsenic trioxide was infused at a 0.15 mg/kg daily dose until complete remission was achieved. After 2 weeks of rest, arsenic trioxide was infused daily for 28 days as a consolidation therapy...
March 2017: Hematological Oncology
https://www.readbyqxmd.com/read/26310513/the-efficacy-of-erythropoietin-mouthwash-in-prevention-of-oral-mucositis-in-patients-undergoing-autologous-hematopoietic-sct-a-double-blind-randomized-placebo-controlled-trial
#20
Hesamoddin Hosseinjani, Molouk Hadjibabaie, Kheirollah Gholami, Mohammadreza Javadi, Mania Radfar, Zahra Jahangard-Rafsanjani, Emadoddin Hosseinjani, Nazanin Shabani, Mohammad Vaezi, Ardeshir Ghavamzadeh
Oral mucositis (OM) as a complication of high-dose chemotherapy is frequently occurred in hematopoietic stem cell transplantation (HSCT) settings. Erythropoietin (EPO) has anti-inflammatory, antioxidant and wound-healing properties and therefore could have an important role in the prevention of OM. We conducted a double-blind, randomized, placebo-controlled trial to evaluate the EPO mouthwash effect on OM incidence and severity in 80 patients with non-Hodgkin's lymphoma, Hodgkin disease (HD) or multiple myeloma, undergoing autologous hematopoietic stem cell transplantation...
March 2017: Hematological Oncology
journal
journal
28626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"